MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVP

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.17
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.58

21 May
2025

0.030

OPEN

$0.58

5.45%

HIGH

$0.58

46,753

LOW

$0.55

TARGET
$0.80 37.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MVP: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 46.3 - 0.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-46.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx33.1 M
Book Value Per Share xxxxxxxxxxxxxxx51.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.8 M
Net Profit Margin xxxxxxxxxxxxxxx-123.66 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-64.53 %
Return on Invested Capital xxxxxxxxxxxxxxx-62.50 %
Return on Assets xxxxxxxxxxxxxxx-47.32 %
Return on Equity xxxxxxxxxxxxxxx-64.53 %
Return on Total Capital xxxxxxxxxxxxxxx-25.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx9 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx10 M
Price To Book Value xxxxxxxxxxxxxxx0.76

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx3.2 M
Capex % of Sales xxxxxxxxxxxxxxx9.56 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

30/04/2025

1

Upgrade to Speculative Buy from Hold

$0.80

37.93%

Bell Potter raises its target for Medical Developments International to 80c from 71c, driven by a lower discount rate and adjusted valuation weighting, and upgrades to Speculative Buy from Hold

Management delivered a surprise positive operating cash flow of approximately $1.7m in the March quarter, observe the analysts. This represents a $5.6m improvement year-on-year, and turns year-to-date cash flow to a positive $0.9m, up $11m from the prior year.

Cash flows benefited from favourable debtor payment timing, but Bell Potter cautions the June quarter may show negative cash flow as working capital shifts and inventory is built for the US respiratory season.

A new distribution agreement has been signed with Ethypharm to accelerate Penthrox sales in France, leveraging Ethypharm’s established position in pain and addiction therapies across Europe, explains Bell Potter.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.01 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.02 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MVP STOCK CHART

FNArena News on MVP

1
Weekly Ratings, Targets, Forecast Changes – 02-05-25

May 05 2025 - Weekly Reports
2
Weekly Ratings, Targets, Forecast Changes – 28-03-25

Mar 31 2025 - Weekly Reports
3
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia
4
Australian Broker Call *Extra* Edition – Mar 08, 2023

Mar 08 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Nov 01, 2022

Nov 01 2022 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps